Bioidentical hormones: Help or hype?
Bioidentical hormones are promoted as being safer than FDA-approved hormones, but their production is not regulated and their claims of effectiveness have not yet been substantiated by long-term clinical trials.
Bioidentical hormones are promoted as being safer than FDA-approved hormones, but their production is not regulated and their claims of effectiveness have not yet been substantiated by long-term clinical trials.
Yhough ringing or other noise in the ears is bothersome, it is rarely indicative of a more serious health issue. There are ways to manage the condition or minimize its impact.
In a trial, annual screening for ovarian cancer did not result in fewer cases or fewer deaths.
A study of older adults who took daytime naps found that their total sleep time increased without causing daytime drowsiness.
I developed painful red bumps over my shins. My doctor has diagnosed me with erythema nodosum. What causes this? What can I expect?
Postpartum depression is a common condition following childbirth. Unfortunately many women who experience it do not seek treatment.
A study comparing treatments for chronic fatigue syndrome found that cognitive behavioral therapy yielded the best results, but the benefit from any of the treatments was modest.
I heard a news story about people using bath salts to get high. How is that possible? My husband and I have two teenagers. Should we talk with them about this?
A Harvard Medical School psychology instructor and author offers advice for dealing with perfectionist tendencies in a constructive way.
An experimental drug shows promise at slowing the growth of ovarian cancer, a study says. The drug is called olaparib. It blocks a natural enzyme known as PARP (Poly ADP ribose polymerase), making chemotherapy more effective. The drug was tested in a study of 65 women with ovarian cancer. The women received olaparib twice a day for 4 weeks. They were also divided into 2 groups: those who carry a gene mutation known as BRCA 1 or BRCA 2, and those who do not. The treatment was most effective in those with the gene mutation. Tumors shrank for 41% of them. It was also helpful for 24% of those without the mutation. The study appears in The Lancet. HealthDay News reported on it Aug. 21.